Angelica Welch

November 29, 2018

The acceptance of next-generation sequencing (NGS) platforms and cell-free DNA (cfDNA) have enabled oncologists to more specifically target genetic mutations in the treatment of patients with non–small cell lung cancer (NSCLC), according to Benjamin P. Levy, MD.

November 27, 2018

The optimal duration of treatment for patients with HER2-positive breast cancer has been called into question by recent findings from the NSABP B-52, PERSEPHONE, and APT clinical trials.

November 12, 2018

The FDA has granted a priority review designation to a supplemental new drug application (sNDA) for olaparib (Lynparza) tablets for use as a maintenance therapy in patients with newly-diagnosed, BRCA-positive advanced ovarian cancer who achieved a complete or partial response to standard frontline platinum-based chemotherapy.

November 06, 2018

The PARP inhibitor olaparib (Lynparza) significantly improved progression-free survival (PFS) as frontline maintenance therapy in women with BRCA-positive advanced ovarian cancer, according to findings reported at the 2018 European Society of Medical Oncology Congress.

October 10, 2018

The FDA’s Oncologic Drugs Advisory Committee (ODAC) recommended approval of CT-P10, a biosimilar for the monoclonal antibody rituximab (Rituxin), for 3 non-Hodgkin lymphoma indications in a 16-0 vote.

September 25, 2018

Frontline therapy may be able to be avoided in asymptomatic, young, fit patients with mantle cell lymphoma (MCL), explained Simon Rule, MD, PhD, in a presentation during the 2018 SOHO Annual Meeting. Active treatment in this patient population could potentially lead to unnecessary toxicities, he added.

September 21, 2018

Two trials have shown that carfilzomib (Kyprolis)-based regimens appeared to be a safe and effective treatments for all patients with multiple myeloma, according to updated data from the ASPIRE and ENDEAVOR trials presented at the 2018 SOHO Annual Meeting.

June 06, 2018

Next-generation sequencing (NGS) in metastatic non–small cell lung cancer (NSCLC) can save Center for Medicare and Medicaid Services (CMS) payers $1.4 million to $2.1 million.

March 08, 2018

A wave of novel treatments and FDA approvals has recently swept through the HER2-positive breast cancer space. Kimberly L. Blackwell, MD, oncologist at Duke Cancer Institute, discusses these recent advancements.

November 29, 2017

Although much success has been seen, 15% of patients with HER2-positive breast cancer will recur. Outcomes for those patients need to be improved, said Sara M. Tolaney, MD.